Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/29/2026, 12:00:00 AM
Announced on 2026-04-29 that its self-developed Class 1 new drug, HS-10522 tablets, received two clinical trial approvals from China's NMPA for treating uncontrolled hypertension and primary aldosteronism. Medium importance is assigned as clinical approvals for new drugs typically impact price by >=5%.
Korean Translation
2026-04-29에 자체 개발 1급 신약 HS-10522정이 중국 국가약품감독관리국(NMPA)으로부터 '조절되지 않는 고혈압' 및 '원발성 알도스테론증' 치료를 위한 2건의 임상시험을 승인받았음을 발표함. 신약 임상 승인은 통상 5% 이상의 주가 영향을 미치므로 'Medium'으로 분류함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
On June 16, 2026, the Annual General Meeting 2026 is scheduled; low impact expected as it is a routine corporate event, scheduled.
6/16/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. This event is expected to have a medium impact as earnings reports typically drive significant price volatility scheduled.
6/3/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Earnings Release
On May 18, 2026, publication of the full-year results for the 2025/26 fiscal year is scheduled. The company expects growth to be at the lower end of guidance; high impact expected as earnings are a key market driver, expected.
5/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM